According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were ...

Biocon eyes global insulin leadership as rivals pivot to GLP-1 therapies, betting on capacity gaps, pricing advantage and ...

Bosaya(TM) and Aukelso(TM) (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with an interchangeable designation -- Potential benefit to ...

Biocon aims to become the world's leading insulin company, capitalising on larger pharmaceutical rivals' strategic shift ...

Biocon, a biopharma giant, is escalating its artificial intelligence adoption across all operations to expedite drug ...

Biocon is introducing Bosaya (denosumab-kyqq), a biosimilar to Prolia, and Aukelso (denosumab-kyqq), a biosimilar to Xgeva.

Strong traction in broking, retail consumption, and real estate demand will keep markets driven by stock-specific action.

Biocon’s fair value estimate has been adjusted slightly, moving from ₹421.60 to ₹420.74, a change of less than 1% that keeps the price target broadly in line with earlier expectations. Analysts ...

The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...

Biocon Pharma Ltd, a division of Biocon Ltd, received USFDA approval for its generic dapagliflozin tablets. These tablets aid in managing blood sugar levels in adults with type 2 diabetes. This ...

Biocon's Siddharth Mittal steps down as MD & CEO; Shreehas Tambe, a 30-year company veteran with 61 patents, takes over from April 1.

Biocon announced the launch of Bosaya™ and Aukelso™ (denosumab-kyqq) in the U.S. and available by prescription nationwide.